Humana Inc. $HUM Position Lifted by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management increased its Humana stake by 20,126.8% in the third quarter, purchasing 1.25 million additional shares to own approximately 1.05% of the company, valued at $479.1 million.
• Humana reported quarterly EPS of $7.61, beating estimates of $7.27, while revenue rose 26.2% year over year to $40.89 billion. The company also declared a quarterly dividend of $0.885 per share, representing a 0.8% yield.
• Analyst sentiment is broadly favorable, with Humana receiving a “Moderate Buy” consensus rating and a $453.30 average price target; however, the planned discontinuation of 37 PPO plans for 2027 could create member-transition and retention risks.

Assenagon Asset Management S.A. raised its stake in Humana Inc. (NYSE:HUM - Free Report) by 20,126.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,255,479 shares of the insurance provider's stock after buying an additional 1,249,272 shares during the quarter. Assenagon Asset Management S.A. owned approximately 1.05% of Humana worth $479,053,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Mather Group LLC. lifted its holdings in Humana by 58.3% in the third quarter. Mather Group LLC. now owns 527 shares of the insurance provider's stock valued at $201,000 after acquiring an additional 194 shares during the last quarter. First Citizens Bank & Trust Co. acquired a new position in shares of Humana in the 3rd quarter valued at $804,000. Krilogy Financial LLC lifted its stake in shares of Humana by 11.2% in the 3rd quarter. Krilogy Financial LLC now owns 2,448 shares of the insurance provider's stock valued at $934,000 after purchasing an additional 246 shares during the last quarter. Chapin Davis Inc. purchased a new position in shares of Humana during the 3rd quarter worth $12,323,000. Finally, GAMMA Investing LLC grew its holdings in shares of Humana by 27.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,996 shares of the insurance provider's stock worth $762,000 after purchasing an additional 429 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Performance

Shares of HUM stock opened at $431.99 on Friday. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.62. Humana Inc. has a 52 week low of $163.11 and a 52 week high of $456.50. The stock has a market capitalization of $51.87 billion, a PE ratio of 24.85, a P/E/G ratio of 2.63 and a beta of 0.74. The firm has a 50 day moving average of $393.53 and a two-hundred day moving average of $341.92.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%. The business had revenue of $40.89 billion for the quarter, compared to analysts' expectations of $40.58 billion. During the same period last year, the firm earned $6.27 earnings per share. The company's revenue for the quarter was up 26.2% compared to the same quarter last year. On average, research analysts predict that Humana Inc. will post 9.03 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 27th. Shareholders of record on Friday, October 30th will be given a $0.8850 dividend. The ex-dividend date of this dividend is Friday, October 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.8%. Humana's dividend payout ratio is currently 33.49%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Cantor Fitzgerald raised shares of Humana from a "neutral" rating to an "overweight" rating and upped their target price for the company from $300.00 to $460.00 in a research report on Wednesday, October 7th. Morgan Stanley raised shares of Humana from an "underweight" rating to an "overweight" rating in a research note on Friday, October 9th. TD Cowen lifted their price target on shares of Humana from $350.00 to $370.00 and gave the company a "hold" rating in a research report on Friday, July 31st. Piper Sandler raised shares of Humana from a "hold" rating to an "overweight" rating and set a $463.00 price target on the stock in a research note on Thursday, July 30th. Finally, Royal Bank Of Canada upped their price objective on shares of Humana from $246.00 to $415.00 and gave the stock a "sector perform" rating in a report on Thursday, July 9th. Twenty-one research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $453.30.

Humana News Roundup

Here are the key news stories impacting Humana this week:

• Positive Sentiment: BlackRock partnership provides substantial capital: BlackRock is reportedly investing approximately $2.8 billion for a majority stake in nearly 150 CenterWell senior primary-care clinics. The transaction should reduce Humana’s capital burden, improve liquidity and help fund CenterWell’s expansion while allowing Humana to retain an economic interest. BlackRock to buy majority stake in Humana’s CenterWell clinics for $2.8 billion
• Positive Sentiment: CenterWell growth prospects strengthened: The joint venture is expected to support the rollout and development of additional senior-care clinics, reinforcing Humana’s strategy of expanding primary-care delivery for older adults. Humana's CenterWell Expansion Gets a Boost From BlackRock's Capital
• Positive Sentiment: Analyst support: A Mizuho analyst reportedly expects Humana’s stock to rise, adding to the favorable sentiment surrounding the company’s strategic initiatives. Humana Stock Price Expected to Rise, Mizuho Analyst Says
• Neutral Sentiment: Humana announced or received attention for a Medicare Advantage coverage policy expanding access to AngioDynamics’ NanoKnife cancer treatment. The move may enhance member benefits and care options, but its direct financial impact appears limited. AngioDynamics Announces Humana Medicare Advantage Coverage Policy
• Negative Sentiment: 2027 plan exits could create disruption: Humana plans to discontinue 37 PPO plans for 2027. Although affected members may have a time-limited right to enroll in Medigap without medical underwriting, plan exits could lead to member attrition, regulatory scrutiny and transition costs. Humana Will Drop 37 PPOs for 2027

Humana Profile

Humana Inc is a health and well-being company headquartered in Louisville, Kentucky. Founded in 1961, the company began as a nursing home operator before expanding into hospitals and health insurance. Today, Humana primarily provides health insurance products and healthcare services for older adults, individuals, military families and other members in the United States.

Humana's insurance business offers Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid coverage in select markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.